Biotechnology company using artificial intelligence and experimental biology to discover potential treatments for genetic diseases.
Recursion Pharmaceuticals, Inc. operates as an innovative clinical-stage biotechnology company that pioneers drug discovery by leveraging advancements in biology, chemistry, automation, data science, and engineering. Headquartered in Salt Lake City, Utah, the company is committed to decoding biological processes to transform how therapeutic treatments are developed and applied.
At the forefront of Recursion Pharmaceuticals' pipeline is REC-994, currently undergoing Phase IIa clinical trials for the treatment of cerebral cavernous malformation. The company also develops REC-2282 aimed at addressing neurofibromatosis type 2, REC-4881 targeting familial adenomatous polyposis, and REC-3599 in Phase I clinical trials for GM2 gangliosidosis. In addition, Recursion's preclinical stage products include REC-3964 for Clostridium difficile colitis, REC-64917 for neural or systemic inflammation, REC-65029 for HRD-negative ovarian cancer, REC-648918 to enhance anti-tumor immune response, REC-2029 for Wnt-mutant hepatocellular carcinoma, REC-14221 for solid and hematological malignancies, and REC-64151 for immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer.
The company's strategic collaborations include partnerships with Bayer AG, the University of Utah Research Foundation, Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. These collaborations bolster Recursion Pharmaceuticals' research and development efforts, accelerating the progress of its diverse pipeline of therapeutic candidates.
Founded in 2013, Recursion Pharmaceuticals continues to push boundaries in biotechnology with a focus on innovative drug discovery. By integrating cutting-edge technologies and fostering strategic collaborations, the company aims to deliver transformative therapies that address critical unmet medical needs across a spectrum of diseases.